Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024

AETHLON MEDICAL INC

Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
Trial at Medanta Medicity Hospital, Gurugram, India; Dr. Ashok K. Vaid and Dr. Puneet Sodhi as investigators.
Patient recruitment expected Q4 2024; primary endpoint is safety, with exploratory EV reduction analyses.
This adds to prior Australian ethics approvals and DCGI No Objection Certificate for the oncology trial.
Hemopurifier designed to remove tumor-derived extracellular vesicles that may drive resistance to PD-1 inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.